| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Alkermes Plc (ALKS) has 14 insiders with recent SEC Form 4 filings, including 0 buys and 11 sells. ALKS is classified in the Pharmaceuticals industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| VP | 231.6K | $10.42M | - | |
| CFO | 158.7K | $7.14M | - | |
| VP | 111.5K | $5.02M | - | |
| COO | 27.9K | $1.26M | - | |
| Dir | 25.7K | $1.16M | -2,000 |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Nov 1, 2017 | Mitchell Paul J | Director | Sale+OE | 1,000 | $49.16 | $49,160.00 | -11.1% | |
| Nov 1, 2017 | Landine Michael J | SVP, Corp Dev., Alkermes, Inc. | Sale+OE | 15,000 | $48.71 | $730,687.50 | -8.4% | |
| Oct 2, 2017 | Mitchell Paul J | Director | Sale+OE | 1,500 | $50.64 | $75,960.00 | -15.8% | |
| Sep 11, 2017 | Biberstein Kathryn L | Evp/ Cao/ CCO Alks Inc; Sec Alks | Sale+OE | 13,566 | $51.29 | $695,817.06 | -10.4% | |
| Sep 1, 2017 | Mitchell Paul J | Director | Sale+OE | 1,500 | $50.77 | $76,155.00 | -15.8% | |
| Aug 1, 2017 | Mitchell Paul J | Director | Sale+OE | 1,500 | $54.91 | $82,365.00 | -15.8% | |
| Jul 3, 2017 | Mitchell Paul J | Director | Sale+OE | 1,500 | $58.11 | $87,165.00 | -15.8% | |
| Jun 8, 2017 | Stejbach Mark | Svp/ Chief Comm Off, Alks Inc | Sale+OE | 10,000 | $60.34 | $603,352.00 | -18.5% | |
| Jun 8, 2017 | Cooke Shane62 | President, Alkermes Plc | Sale+OE | 10,000 | $60.33 | $603,333.00 | -11.8% | |
| Jun 1, 2017 | Mitchell Paul J | Director | Sale+OE | 1,500 | $57.49 | $86,235.00 | -15.8% |